Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan Long-Term Safety in PAH and CTEPH (UMBRELLA)
NCT03422328Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Apr 2018
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of macitentan in pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Actelion Pharmaceuticals Ltd. Started Apr 2018; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT03422328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422328.